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Hepatitis B seroprevalence in the U.S. military and its impact on
potential screening strategies

ABSTRACT
Introduction
Knowledge of the contemporary epidemiology of hepatitis B virus (HBV) infection among military personnel can inform
potential Department of Defense (DoD) screening policy and infection and disease control strategies.
Materials and Methods
HBV infection status at accession and following deployment was determined by evaluating reposed serum from 10,000
service members recently deployed to combat operations in Iraq and Afghanistan in the period from 2007 to 2010. A
cost model was developed from the perspective of the Department of Defense for a program to integrate HBV infection
screening of applicants for military service into the existing screening program of screening new accessions for vaccinepreventable infections.
Results
The prevalence of chronic HBV infection at accession was 2.3/1,000 (95% CI: 1.4, 3.2); most cases (16/21, 76%)
identified after deployment were present at accession. There were 110 military service-related HBV infections identified.
Screening accessions who are identified as HBV susceptible with HBV surface antigen followed by HBV surface antigen
neutralization for confirmation offered no cost advantage over not screening and resulted in a net annual increase in cost
of $5.78 million. However, screening would exclude as many as 514 HBV cases each year from accession.
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Hepatitis B seroprevalence in the U.S. military

Conclusions
Screening for HBV infection at service entry would potentially reduce chronic HBV infection in the force, decrease the
threat of transfusion-transmitted HBV infection in the battlefield blood supply, and lead to earlier diagnosis and linkage
to care; however, applicant screening is not cost saving. Service-related incident infections indicate a durable threat, the
need for improved laboratory-based surveillance tools, and mandate review of immunization policy and practice.

MATERIALS AND METHODS
Ethical Considerations

This investigation was endorsed by the Armed Services Blood
Program Office and executed by public health, clinical, and
research partners from each of the services in response to
a formal tasking by the Joint Staff Surgeon to define the
epidemiology of HBV and hepatitis C virus in the deployed
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force. The Walter Reed Army Institute of Research Institutional Review Board reviewed the investigation protocol and
determined that it was a public health activity and not human
subjects research (no. 1822).
Seroepidemiology
A detailed description of the methods have been reported
previously by Brett-Major et al.15 Briefly, a random sample
of 10,000 Army, Air Force, Navy, and Marine Corps service
members who ended their most recent deployment to combat operations in Iraq and Afghanistan from October 2007
through October 2010 and who had sufficient sera that had
been collected at time points after deployment and at the
time of service entry/accession and reposed in the DoD serum
repository was identified and relevant archived deidentified
personnel, deployment, and health data from the Defense
Medical Surveillance System were obtained.16
Case Definitions
The following definitions of HBV infection were entered into
the cost model: (1) probable chronic HBV infection (referred
throughout as chronic HBV): both HBsAg positive and HBV
deoxyribonucleic acid (DNA) positive, (2) possible chronic
HBV infection: HBsAg positive, (3) immune to HBV infection due to vaccination: HBV surface antibody (HBsAb) reactive and HBsAg negative and HBV core antibody (HBcAb)
nonreactive, (4) immune to HBV infection due to natural
infection: HBsAb and HBcAb reactive and HBsAg negative,
and (5) susceptible to HBV infection: HBsAb and HBcAb
nonreactive and HBsAg negative. Borderline and missing
results were assumed to be negative.
In addition, the following case definition of service-related
incident HBV infection was utilized: possible incident HBV
infection: HBV susceptible or vaccine-immune at accession
and probable chronic HBV infection or immune due to natural
infection at postdeployment time point.
Laboratory Measures
HBV infection status was determined in a stepwise fashion
beginning with the evaluation of reposed serum at the postdeployment time point.15 Serum samples, stored at –30◦ C,
were retrieved from the DoD serum repository. Serological
testing of postdeployment samples was performed for antibody to hepatitis B core antigen (BIO-RAD MONOLISA
Anti-HBc EIA, Hercules, CA), hepatitis B surface antibody
(MONOLISA Anti-HBs EIA), and for hepatitis B surface
antigen (HBsAg) (BIO-RAD GS HBsAg EIA 3.0). Due to the
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INTRODUCTION
The use of emergent whole blood transfusion has been an
important feature of combat casualty resuscitative care in
the recent military conflicts in Iraq and Afghanistan. The
risk of transfusion-transmitted infections associated with this
practice appears to be low.1–3
The seroprevalence of hepatitis B virus (HBV) infection
among military service members has not previously been
determined. Current recommendations from the U.S. Centers
for Disease Control and Prevention and U.S. Preventive Services Task Force are to screen persons at increased risk for
infection and to perform periodic screening of those with ongoing risk who are not vaccinated.4–6 Current Department of
Defense (DoD) policy states that applicants with current acute
or chronic hepatitis or hepatitis in the preceding 6 mo do not
meet the accession standard.7,8
In 2012, the Department of the Navy expanded its accession entry screening of bloodborne pathogens to include HBV.
All applicants to the Navy and Marine Corps are screened
for chronic HBV infection and disqualified when screening
results are confirmed.9 Army and Air Force regulations are
consistent with the DoD policy but no population-level laboratory screening is performed in either service.10,11
Universal HBV vaccination of new accessions into the
military was initiated in 2002.12 Current practice is to screen
new accessions for the evidence of immunity to HBV and
to immunize those identified as susceptible. In 1991, the
Advisory Committee on Immunization Practices (ACIP) recommended universal vaccination of infants. Subsequent recommendations from the ACIP included (1) 1994: previously
unvaccinated children aged 11 to 12 yr old and (2) 1997: all
unvaccinated aged 0 to 18 yr.13,14
We assessed the contemporary epidemiology of HBV in
recently deployed military forces in order to identify the burden of infection in the force and the potential threat posed by
HBV-infected personnel to the emergent, non–Food and Drug
Administration battlefield blood supply. Findings are intended
to inform potential screening strategies and the development
of HBV infection control measures.

Hepatitis B seroprevalence in the U.S. military

Statistical Methods
Prevalence rates of chronic HBV at postdeployment per 1,000
service members were assessed and 95% confidence intervals
(CIs) were provided. Asymptotic CIs are reported; these are
replaced by exact CIs when there are no cases or the lower
limit of the asymptotic confidence interval is zero. In order to
account for changes in ACIP HBV immunization recommendations and to account for differential vaccination coverage by
time of entry into service based on birth year, data for service
members born in or after 1979 were analyzed separately from
those for members born before 1979. In addition, incidence
rates for HBV per 1,000 service members were assessed
for those service members who were susceptible, vaccineimmune, or identified as HBV-uninfected after deployment
and did not have test results generated at the accession time
point. Results are provided separately by whether or not the
service member was accessioned before 2002. The rate of
incident HBV infections per person-year was calculated as
the total number of cases observed divided by the number of
years from the later of initial entry time into either active or
reserve/guard duty and the year of the postdeployment serum
sample and converted to a rate per 100,000 person years. Data
sets were managed and analyzed utilizing Statistical Analysis
Software version 9.4 (SAS, Cary, NC).

Cost Modeling
We developed a decision tree reflecting three possibilities:
(1) “status quo”- screen all applicants for the evidence of
immunity with HBsAb and provide a complete 3 shot vaccine
series to those without the evidence of immunity; (2) screen
all applicants who screen negative for the evidence of HBV
immunity for HBV infection with HBsAg and confirmation by
HBsAg neutralization; (3) screen only those applicants born
outside of the continental United States who screen negative
for the evidence of HBV immunity for HBV infection with
HBsAg and confirmation by HBsAg neutralization. A conservative cost model was developed using the observed estimate
of chronic HBV infection rather than possible chronic HBV
in order to avoid overestimating prevalence.
The following general assumptions impacted the construction of the cost model.
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• With no applicant screening, accessions with chronic HBV
infection will enter military service and generate health
care costs.
• With either screening strategy (2) or (3) above, the number of accessions with chronic HBV infection who enter
military service will be smaller than with no screening.
• Some applicants’ HBV infection status will be misclassified as screening is neither 100% sensitive nor specific.
Specific assumptions and inputs into the cost model were
derived utilizing the seroprevalence observed in this study
and various costs in 2015 U.S. dollars and relevant statistics
drawn from within the DoD and the peer-reviewed scientific
literature (Tables I and II). We assumed that the prevalence
among all applicants would be the same as the prevalence
observed among our study population.
We assumed that all applicants undergo HBV screening
before accession. It is current practice to screen all new
accessions for vaccine-preventable infections, including HBV,
and to provide booster immunization as needed to individuals
based on these results. It is not current practice to screen
all applicants for immunity to vaccine-preventable infections.
The assumption that HBsAb screening would be performed
on all applicants (ie, “status quo”) was made for the purposes
of this model. Based on review of recent historical data, the
applicant pool size was assumed to be the sum of 232,000
accessions and 95,000 nonaccessions.17
We assumed a 40% (30.6%, 46.5%) prevalence of HBV
immunity among applicants based on recent unpublished data
obtained from public health authorities at selected Army and
Air Force basic training sites (Susan Varner, Fort Leonard
Wood, personal communication). We also assumed that all
accessions who have chronic HBV infection would be identified during their period of military service and treated while
in service. We assumed that 17% of accessions would serve
20 yr and that the remaining 83% would serve an average
of 5 yr.18
We assumed all individuals with HBV infection would
progress through a series of stages of HBV infection and
disease states from immunotolerant through chronic infection,
cirrhosis, hepatocellular carcinoma, liver transplant, and death
using previously published estimates of disease state transition
probabilities.19 All individuals identified as immunotolerant,
with asymptomatic HBV infection, or evidence of seroconversion were assumed to get no treatment. Those with chronic
HBV or compensated cirrhosis were assumed to be treated
with tenofovir, a high-cost nucleotide with a low chance
of developing resistance, every year until seroconversion or
progression to more advanced disease states. Using previously
published data,19 the annual rate of spontaneous conversion
from immunotolerant and asymptomatic HBV was assumed
to be 10%, and the annual rate of spontaneous conversion for
individuals on therapy was assumed to be 21% save those
with decompensated cirrhosis, where it was assumed to be
5%. Treatment costs for each disease state and tenofovir were
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limitations of available reposed serum, HBsAg neutralization
was not performed. HBV nucleic acid testing was performed
on samples that tested repeatedly reactive for HBsAg. HBV
DNA was purified using QIAamp DNA blood mini kit (Qiagen Inc., Valencia, CA) and quantified using HBV ASR TaqMan reagents (Roche COBAS HBV, Roche Diagnostics Inc.,
Indianapolis, IN). When a postdeployment sample screened
positive for the evidence of chronic HBV infection or immune
to HBV due to natural infection, an accession sample was also
tested under the same algorithm.

Hepatitis B seroprevalence in the U.S. military

TABLE I. Model Inputs
Name

Base Case

Distribution

Source

(0.0018–0.0028)

Uniform

Current study

(1.0–1.0)
(0.9973–0.9987)
(0.9852–1.0)
(0.962–0.964)
(0.25–0.45)
(0.71–0.97)
(0.71–0.71)

Uniform
Uniform
Uniform
Uniform
Uniform
Normal
Uniform

BIO-RAD GS HBsAg EIA 3.0
BIO-RAD GS HBsAg EIA 3.0
BIO-RAD MONOLISA Anti-HBs EIA
BIO-RAD MONOLISA Anti-HBs EIA
Eckman et al.19
Defense Business Board18
AMSARA17

(0.3–0.5)
(0.052–0.102)
(0.0078–0.0178)

Uniform
Uniform
Uniform

Susan Varner, personal communication
Current study
Current study

Eckman et al.19

DNA, deoxyribonucleic acid; HBV, hepatitis B virus; AMSARA, Accession Medical Standards Analysis and Research Activity.

TABLE II. Costs Used in Markov Model
Name
Rerecruitment costs
MEPS processing
Anti-HBs
HBsAg
HBsAg neutralization
Vaccine

Tenofovir treatment
Chronic HBV
Compensated cirrhosis
Decompensated cirrhosis
Hepatocellular carcinoma
Transplant yr 1
Transplant yr 2+
Death

Base Case
$23,000
$690.82
$4.50
$4.00
$30.00
$56.46

$9,558.81
$1,298.82
$1,460.26
$19,550.87
$58,535.67
$192,938.03
$33,693.65
$0.00

Source
AMSARA, U.S. Army 2014
AMSARA, U.S. Army 2014
MHRP, Personal communication
MHRP, Personal communication
MHRP, Personal communication
Air Force: Webber, B, Joint Base San Antonio; Navy:
Beckett, C, Navy Bloodborne Infection Management
Center, Personal communication
Eckman et al.19
Eckman et al.19
Eckman et al.19
Eckman et al.19
Eckman et al.19
Eckman et al.19
Eckman et al.19
Current study

HBsAg, HBV surface antigen; HBV, hepatitis B virus; AMSARA, Accession Medical Standards Analysis and Research Activity; MHRP, U.S. Military
HIV Research Program; MEPS, Military Entrance Processing Stations.

obtained from a previously published report and were inflated
to 2015 U.S. dollars using the medical care component of the
U.S. Consumer Price Index.19
Last, we assumed that applicants identified with chronic
HBV through a screening program and not permitted to accession would have to be replaced with another fully qualified
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individual and that this would incur rerecruitment costs of
nearly $23,000 per individual (Thomas J, U.S. Army Training
and Doctrine Command, unpublished data).
The net cost of screening was determined by the cost of
screening, the savings from avoiding treatment of those with
HBV infection prevented from entering military service, and
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Demographic and test characteristics
Prevalence of DNA-positive HBV
0.0023
detected at Screening
Surface antigen sensitivity
1.0
Surface antigen specificity
0.998
Surface antibody sensitivity
0.9926
Surface antibody specificity
0.963
Enter asymptomatic carrier
0.35
Stay 5 yr in service
0.83
0.71
Probability that a recruited service
member passes medical screening
and boot camp and proceeds to
military service
Detectable HBV immunity
0.4
Probability of being foreign-born
0.077
Prevalence of HBV infection in
0.0128
foreign-born
Markov model HBV disease progression probabilities
Progression through stages of HBV
infection (stratified by HBV DNA
levels < 2 k, 2–20 k, and > 20 k)
from immunotolerant through
chronic infection, cirrhosis,
hepatocellular carcinoma, liver
transplant, and death using
previously published estimates of
disease state transition probabilities

Range

Hepatitis B seroprevalence in the U.S. military

RESULTS
Study Population

Of the 10,000 randomly selected service members, 9,993
had complete postdeployment HBV test results generated
(Supplementary Table 1). Overall, most at accession were less
than 25 yr old (73%), white (74%), males (89%), in the active
component (76%), and in the Army (54%). This sample was
representative of the applicant population.17
Birth and Accession Cohort Demographics
Among the study population, 3,850 (39%) were born before
1979 (older birth cohort). Those who were born in/after
1979 (younger birth cohort) were more frequently white
(75% vs. 71%), of lower rank (95% vs. 81% were E01-E04),
single (93% vs. 75%), in the Marine Corps (15% vs. 8%)
and less likely to have health care occupations (2% vs. 5%)
(Supplementary Table 2). Compared with those who entered
military service before 2002 (24%), those who entered in
2002 or later were more likely to be younger (75% vs. 19%
born in/after 1979), less educated (81% vs. 73% with a high
school education or less), of lower rank (94% vs. 74% were
E01-E04), serving in the active component (81% vs. 59%),
Marines (14% vs. 6%), and less likely to have health care
occupations (3% vs. 5%) (Supplementary Table 3).
HBV Cases—Postdeployment
There were 21 chronic HBV cases identified at the postdeployment time point; of these, 20 (95%) had some evidence
of prior HBV infection present at accession. There were 26
possible chronic HBV cases present among service members
tested at the postdeployment time point; of these, 14 (54%)
had some evidence of prior HBV infection present at accession
(Supplementary Table 1).
HBV Prevalence—Older Birth Cohort
There were 14 chronic HBV cases present at the postdeployment time point. Most cases were male (64%) and
less than 30 yr old at accession (86%). Prevalence rates
were highest among women (12/1,000, 95% CI: 1.5/1,000–
22.4/1,000), service members of black race (12.9/1,000, 95%
CI: 4.5/1,000–21.4/1,000) or other race (12.2/1,000, 95% CI:
0.3/1,000–37.3/1,000), sailors (7.4/1,000, 95% CI: 0.9/1,000–
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13.9/1,000), and foreign-born service members (19.5/1,000,
95% CI: 2.6/1,000–36.3/1,000) (Supplementary Table 2). Of
the 14 chronic infections at postdeployment, 11 were chronic
(79%) at the time of accession, 2 were possible chronic
at accession, and 1 had natural immunity at accession. At
accession, the prevalence of chronic HBV was 3.9/1,000 (95%
CI: 1.9/1,000–5.9/1,000).
HBV Prevalence—Younger Birth Cohort
There were 7 chronic HBV cases present at the postdeployment time point. Cases were more frequently male (71%),
born in the continental United States (86%), soldiers (57%),
and in the active component (71%). Six of 7 (86%) were
either possible chronic (n = 1) or chronic (n = 5) at the
time of accession. At accession, the prevalence of chronic
HBV was 1.3/1,000 (95% CI: 0.4/1,000–2.2/1,000). Two of
the 8 cases (25%) of chronic HBV infection at accession
were identified among individuals born outside of the United
States. Individuals born outside of the United States made
up 8.4% of the total cohort of those born during/after 1979
(515/6,143). Prevalences were highest among those with
race of “other” 5.1/1,000 (95%CI: 1.1/1,000–14.9/1,000)
(Supplementary Table 2).
HBV Incidence
There were 110 possible incident HBV infections among the
9,780 service members uninfected at accession
(Supplementary Table 3). Most incident infections resulted
in immunity due to natural infection. Among those, there was
one (1%) probable chronic HBV infection and 109 (99%)
with the evidence of immunity due to natural infection. There
were 75 susceptible at accession of whom 1 seroconverted
to probable chronic HBV infection and 74 seroconverted to
immune due to natural infection. And, there were 35 immune
due to vaccination at accession who seroconverted to immune
due to natural infection (Supplementary Table 1).
Costs—Screening Strategy No. 1
With no screening, the cost to the DoD of treating the estimated 534 cases of chronic HBV cases from a single year’s
accession cohort of 232,000 was $7.08 million.
Screening Strategy No. 2
The cost of screening all 327,000 applicants is $0.78 million.
Screening would identify 514 (96%) of the 534 cases of
chronic HBV infection among the applicant population who
accession, which would result in a treatment cost avoided of
$6.8 million. Thus, the total cost of treatment is reduced from
$7.1 million to $0.26 million by a screening program that
costs $0.78 million. However, the additional $11.82 million in
recruiting costs required to replace these 514 applicants who
do not accession results in a total cost of $12.86 million.
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the costs of rerecruiting and replacing applicants identified
with positive HBV screening test results who are not allowed
to enter.
Sensitivity analyses were performed using ranges of possible values for all assumed costs and probabilities using
existing literature and personal communication. Our assumption that all accessions who enter military service with HBV
infection would be identified before separation from service
was compared with recent historical data.20

Hepatitis B seroprevalence in the U.S. military

Screening Strategy No. 3

Sensitivity Analysis

The replacement, or rerecruitment cost, would need to be
lowered to $11,725 in order to make the screening strategy to
screen all applicants cheaper than the status quo. The expected
cost of treating each HBV infected case would need to increase
to $22,658 in order to make the screening strategy to screen
all applicants cheaper than the status quo.
A Markov Chain Monte Carlo simulation was performed
to simulate how frequently in a 1,000 simulation trials each
screening option scenario is found to be the cheapest option.
Using the distributions for all parameters in Tables I and II, the
status quo, no screening was cheapest in 993 of 1,000 trials.

DISCUSSION
The overall prevalence of chronic HBV infection and the
prevalence among the younger cohort of service members
who were born after 1979 that was present at the time of
accession into military service was 2.3/1,000 and 1.3/1,000,
respectively. Thus, there are currently approximately 300 to
500 service members who enter the service each year with
chronic HBV. The cost model is most strongly influenced
by rerecruitment costs to replace an HBV-infected applicant
identified through screening and the treatment costs to the
DoD for a service member with chronic HBV. Screening
for HBV infection at service entry would reduce chronic
HBV infection in the force, may decrease the threat to the
battlefield blood supply, and may lead to earlier linkage to
care. However, applicant screening is not cost saving. As long
as the replacement, or rerecruitment, cost is greater than the
treatment cost, it will not be cost saving for the DoD to screen
applicants for chronic HBV infection.
The observed overall prevalence at accession of 0.23%
(23/9,993) is slightly lower than the estimated prevalence
of HBV infection in the general U.S. population (0.3 to
0.5%).4,21,22 These data are consistent with U.S. national
data with higher rates of infection among nonwhites, older
individuals, and those born outside of the United States.
Among those born during/after 1979 and living in the
United States, all would have been subject to infant/childhood
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The cost of screening only those 17,266 applicants born
outside of the continental United States is $0.08 million.
Screening would identify 222 (42%) of the 534 cases of
chronic HBV infection among the applicant population who
accession, which would result in a treatment cost avoided of
$2.94 million. Thus, the total cost of treatment is reduced from
$7.1 million to $4.14 million by a screening program that
costs $0.08 million. However, the additional $5.11 million in
recruiting costs required to replace these 222 applicants who
do not accession results in a total cost of $9.33 million. The
status quo strategy of no screening results in the lowest overall
cost to the DoD.

vaccination recommendations. The prevalence of chronic
HBV infection at accession for the younger cohort was
0.13% (8/6,143). Observed prevalences were highest among
nonwhites, though the absolute counts were small. Most
cases were among those born in the United States, all of
whom were subject to 1 or more recommendations for
infant/childhood HBV vaccinations and may also have been
immunized at service entry because universal immunization
of new accessions was initiated in 2002. Only 25% (2/8)
of the accession cases identified in this younger cohort
occurred among individuals born outside of the United States.
Individual exposure and risk behavior data were not available.
Specifically, it is unknown what fraction of the U.S. born
individuals in this younger cohort were vaccinated as children
and/or were vaccinated on service entry, and it is unknown
how many were children of immigrants from high prevalence
countries, and/or were members of other groups at increased
risk for HBV infection. Further study is required to determine
risk factors for infection.
The accession prevalence among the older cohort, 0.39%
(15/3,850), was higher. None would have been subject to
infant/childhood vaccination recommendations in the United
States but some may have been immunized at service entry or
immunized during their period of service. Like the younger
cohort, case counts were low. Observed prevalences were
highest among nonwhites and among foreign-born. Onethird (5/15) of the cases of HBV infection at accession were
identified among those who were foreign-born. Here too,
it is unknown what risk factors for HBV infection were
present.
We assumed that all of those who entered military service
with chronic HBV infection would be identified and linked
to care before separation from military service. Actual case
finding of chronic HBV infection appears to be much less than
100%. Many service members with chronic HBV infection
likely enter, complete service, and separate without having
their infection status identified. Case finding of less than 100%
results in lower treatment costs to the DoD, so screening is
likely to be even more unfavorable in terms of cost than this
model would suggest.
The U.S. military screens all new accessions for the evidence of HBV immunity and vaccinates all those with laboratory evidence of susceptibility with a complete 3 dose
vaccine series in order to prevent incident HBV infection.
Postvaccination serologic testing for immunity is not routinely
performed in military personnel.
In this investigation, the rate of incident HBV infections
was 189/100,000 PY’s, which is considerably higher than that
reported among active duty personnel in the period 2007–2016
(126/yr, 10/100,000 person-yr).20 However, direct comparison of these rates is difficult because rates from this study
are based on infection rates among all individuals at risk,
whereas previously reported rates were based only on those
that were identified clinically, which is likely a significant
underestimate since the vast majority of acute HBV infections
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in adults are asymptomatic. These data suggest that incident
HBV infection remains an enduring threat in this population.
There are some potential challenges associated with these
incidence data. False-positive test results would contribute
to an overestimation of incidence, particularly among those
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has a high false-positive rate.23 Future study is warranted in
order to more accurately characterize incident HBV infection
in this highly vaccinated population of young adults. This
is also of great interest in terms of examining the impact
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were subject to infant/childhood vaccine recommendations
and most (76%) were subject to universal HBV immunization
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Current data from a variety of settings suggest that protection from HBV infection following a complete immunization
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the development of other cost beneficial means to optimize
existing HBV immunization practices. For example, screening
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DoD and would result in a substantial net cost. If the HBV
infection treatment landscape changes substantially such that
treatment costs markedly increase, this analysis should be
repeated. Opportunities exist to optimize HBV infection control measures and may benefit from more complete characterization of incident infections. Further study is warranted.
Improvements in the performance of diagnostic tools available
for the determination of HBV infection status would improve
surveillance and public health efforts.
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